Financial Results - Evofem Biosciences, Inc. announced its financial results for the year ended December 31, 2025, on March 11, 2026[4]. Cost Management and Operational Efficiency - The company is focusing on cost of goods sold (COGS) reduction initiatives and expects to see future sales trends improve as a result[8]. - Manufacturing efficiencies are a key area of focus for Evofem to improve overall operational performance[8]. Strategic Initiatives - Evofem is exploring international market expansion and potential strategic alternatives to enhance its financial position[8]. - The company highlighted the importance of obtaining additional financing to support ongoing operations and business development[8]. Risk Factors - The company is aware of risks such as limited cash resources and potential delays in regulatory approvals that could impact future performance[8]. - Evofem's forward-looking statements are based on current assumptions and are subject to known and unknown risks and uncertainties[8]. Corporate Communication - The company has prepared a corporate presentation to provide updates and summaries of its business, available on its website[6]. - The press release and corporate presentation are not intended to be incorporated by reference into any future filings[5]. - The Chief Financial Officer, Ivy Zhang, signed the report on behalf of Evofem Biosciences, Inc.[12].

Product Launch and Market Opportunity - PHEXX, the first and only non-hormonal prescription contraceptive vaginal gel, was launched in the U.S. in September 2020, targeting approximately 15.9 million women who do not want to get pregnant and will not use hormonal contraceptives[21]. - The U.S. contraceptive market was valued at $8.8 billion in 2024 and is projected to reach approximately $12 billion by 2030, with a compound annual growth rate of 4.7%[34]. - An estimated 15.77 million women of reproductive age in the U.S. report using GLP-1 medications, creating a $904 million total addressable market for PHEXX among those also using oral contraceptives[42]. - Approximately 41.6% of all pregnancies in the U.S. are unintended, equating to about 2.3 million unintended pregnancies annually, highlighting the need for effective contraceptive options like PHEXX[44]. - The U.S. market presents the greatest opportunity for PHEXX and SOLOSEC, with a focus on approximately 15.9 million sexually active women using non-hormonal methods and 10.3 million using hormonal contraceptives[72]. - The U.S. market for contraceptives includes approximately 26.2 million women, with 15.9 million not seeking pregnancy and not using hormonal contraceptives, indicating a significant potential market for PHEXX[100]. Product Development and Manufacturing - The company aims to reduce the cost of goods sold (COGS) for PHEXX and SOLOSEC by approximately 55% to 60% by 2027 through new manufacturing contracts[32]. - The company is currently contracted with a leading U.S.-based gel manufacturer to produce PHEXX in compliance with cGMP regulations[130]. - The company reversed a contingent liability of $1.9 million related to the Rush Royalty after the USPTO denied the PTE application, impacting the cost of goods sold[140]. - Evofem relies on third parties for the production of PHEXX and SOLOSEC, which must comply with cGMP requirements[154]. Regulatory and Compliance - The FDA regulates the approval and marketing of drugs, requiring compliance with extensive regulations and potential penalties for non-compliance[150]. - The FDA may withdraw product approvals if compliance with regulatory standards is not maintained[155]. - Regulatory processes for obtaining approvals require substantial time and financial resources, impacting product development timelines[149]. - The FDA's regulations include monitoring and record-keeping activities post-approval, which are critical for maintaining product compliance[151]. - The company must comply with various laws and regulations, including the U.S. Foreign Corrupt Practices Act, which affects international operations[179]. Intellectual Property - The company owns or has exclusive licenses to approximately 35 issued patents and allowed applications related to PHEXX, with some patents expiring as late as 2033[145]. - The company has approximately 20 issued patents and allowed applications related to SOLOSEC, with additional trade secrets and know-how contributing to its competitive position[146]. - The intellectual property for PHEXX includes four U.S. patents, expected to protect the product until 2033[167]. - SOLOSEC is covered by eleven U.S. patents, with protection expected until 2041, and is also protected by NCE-GAIN Exclusivity until September 15, 2027[168]. Market Strategy and Partnerships - The company intends to leverage its U.S. sales force to acquire or in-license additional commercial products to diversify revenue streams and enhance offerings in women's health[33]. - The company has licensed commercial rights to PHEXX and SOLOSEC in the MENA region to Pharma 1, with plans for regulatory approval filings in the UAE in 2025[24]. - The company aims to establish regional and global partnerships for the commercialization of its products, enhancing market access and stakeholder value[128]. - The company is actively working with health plans and PBMs to improve formulary positioning for PHEXX and SOLOSEC, aiming for broader market access[82]. Patient Compliance and Treatment Efficacy - SOLOSEC demonstrated a cure rate of 92.2% for trichomoniasis in women during clinical trials, with male cure rates ranging from 91.7% to 100%[65]. - SOLOSEC's single-dose treatment approach addresses non-compliance issues seen with multi-day regimens, which affect up to 50% of BV patients[61]. - SOLOSEC's one-time oral dosing is expected to improve patient compliance and potentially reduce overall treatment costs[79]. - The company’s commercialization strategy includes leveraging telehealth platforms to provide direct access to PHEXX for women[71]. Financial and Market Access Challenges - Evofem's products depend on third-party payer coverage, with no uniform policy in the U.S. for drug reimbursement, leading to a time-consuming and costly coverage determination process[212]. - Legislative changes, including the ACA and the 2021 Consolidated Appropriations Act, have increased Medicaid rebates and imposed mandatory discounts for Medicare Part D beneficiaries, affecting the pharmaceutical industry[207]. - The Affordable Care Act mandates coverage for FDA-approved contraceptives, including PHEXX, with no out-of-pocket costs for women, effective January 1, 2023[90]. - Evofem anticipates continued pressure on pharmaceutical pricing due to increased emphasis on cost containment measures in the U.S.[215]. Employee and Organizational Structure - As of February 28, 2026, Evofem had a total of 29 full-time employees, with good relations maintained with employees and consultants[218]. - The company faces various risk factors that could materially affect its business, financial position, and trading price of securities[219].

Core Perspective - Evofem's CEO emphasized the need for a "Ground-Up Reset" in women's health during a keynote address at Fierce JPM Week 2026, highlighting the importance of addressing systemic issues in the industry [1] Company Insights - Evofem is actively participating in discussions at major industry events, showcasing its commitment to advancing women's health [1] Industry Trends - The call for a reset in women's health indicates a growing recognition of the need for innovative approaches and solutions within the healthcare sector [1]

Core Viewpoint - Evofem has launched SayVaginaStore.com as part of its 'Say Vagina' campaign, which aims to combat the censorship of female anatomical terms in the media [1] Company Summary - The launch of SayVaginaStore.com represents a strategic expansion of Evofem's campaign to promote open discussions about female anatomy [1] - The initiative highlights the company's commitment to addressing issues related to the representation of women's health topics in public discourse [1] Industry Summary - The campaign reflects a broader movement within the industry to challenge societal norms and promote transparency regarding female health and anatomy [1] - By addressing censorship, the initiative may influence media practices and encourage more inclusive language surrounding women's health issues [1]

Core Insights - Evofem Biosciences is set to launch PHEXX®, a hormone-free contraceptive vaginal gel, in the UAE by 2026 following favorable pricing certificates from the Emirates Drug Establishment [1][2][3] Group 1: Product Overview - PHEXX® is the first and only locally-acting contraceptive gel approved by the FDA, designed to be applied before intercourse and works by maintaining a vaginal pH that is inhospitable to sperm [4] - The product contains lactic acid, citric acid, and potassium bitartrate, and is applied using a pre-filled applicator [4] Group 2: Market Expansion - The issuance of pricing certificates is a significant step for Evofem to diversify its revenue streams and enter new markets, particularly in the GCC and MENA regions [2][3] - Pharma 1, Evofem's licensee, holds exclusive commercialization rights for PHEXX® and SOLOSEC® in six GCC states and plans to expand into 15 additional countries [3] Group 3: Regulatory and Commercial Strategy - Pharma 1 is responsible for all aspects of distribution, sales, marketing, and regulatory approvals for PHEXX® and SOLOSEC® in the licensed territory [3] - The company aims to submit PHEXX® for marketing approval in other licensed countries following its approval in the UAE [3]

Financial Performance - Net sales increased by 10% to $5.0 million in Q3 2025, compared to $4.5 million in the prior year quarter[4] - Operating income of $1.0 million was reported for Q3 2025, a significant improvement from a loss of $2.4 million in the same quarter last year[8] - Total operating expenses decreased by 42% to $4.0 million in Q3 2025, down from $6.9 million in the prior year quarter[7] - The net loss attributable to common stockholders was $1.7 million in Q3 2025, compared to a net loss of $2.4 million in Q3 2024, equating to a loss of $0.01 per share[9] - Restricted cash increased to $0.8 million as of September 30, 2025, compared to $0.7 million as of December 31, 2024[10] - The company reported a total stockholders' deficit of $75.1 million as of September 30, 2025[16] Cost Management - The company achieved a reduction in manufacturing costs by approximately 50% for both PHEXX and SOLOSEC, enhancing per-unit profit and facilitating entry into price-sensitive global markets[4] Regulatory and Clinical Developments - SOLOSEC was submitted for marketing approval in the UAE in Q3 2025 under a License and Supply Agreement with Pharma 1[4] - The company is conducting a Phase 4 clinical trial for SOLOSEC, hypothesizing a 1.75 lower rate of repeat infections compared to metronidazole[4] Corporate Actions - Evofem terminated the merger agreement with Aditxt following stockholder disapproval on October 20, 2025[5]

Core Insights - Evofem Biosciences reported a 10% increase in net sales for Q3 2025, reaching $5.0 million compared to $4.5 million in the same quarter last year, driven by effective sales strategies and marketing initiatives [2][11] - The company achieved operating income of $1.0 million in Q3 2025, a significant improvement from a loss of $2.4 million in the prior year quarter [4][11] - Total operating expenses decreased by 42% to $4.0 million in Q3 2025 from $6.9 million in the same period last year, primarily due to reduced general and administrative costs and a one-time accounting gain [3][11] Financial Performance - Net loss attributable to common stockholders was $1.7 million in Q3 2025, an improvement from a net loss of $2.4 million in Q3 2024, translating to a loss of $0.01 per share compared to $0.02 per share in the prior year [5][15] - The company had restricted cash of $0.8 million as of September 30, 2025, up from $0.7 million at the end of 2024 [6] Product and Market Developments - Evofem is advancing strategies to reduce manufacturing costs by approximately 50% for its products PHEXX and SOLOSEC, which is expected to enhance profitability and facilitate entry into price-sensitive global markets [11] - SOLOSEC has been submitted for marketing approval in the United Arab Emirates under a licensing agreement, indicating ongoing expansion efforts [11] - Patient recruitment is ongoing for a Phase 4 clinical trial evaluating SOLOSEC's effectiveness compared to metronidazole for treating Trichomonas vaginalis, with promising hypotheses regarding cost-effectiveness [11] Corporate Actions - Following a Special Meeting of Stockholders on October 20, 2025, Evofem terminated its merger agreement with Aditxt after stockholders did not approve the transaction [11]

Financial Performance - Product sales for the three months ended September 30, 2025, were $4.952 million, an increase from $4.496 million in the same period of 2024, representing a growth of approximately 10.2%[18] - The net loss attributable to common stockholders for the three months ended September 30, 2025, was $1.680 million, compared to a net loss of $2.370 million for the same period in 2024, indicating an improvement of approximately 29.2%[18] - Net loss for the three months ended September 30, 2025, was $1,569 million, compared to a loss of $2,365 million for the same period in 2024, representing a 33.5% improvement[21] - For the nine months ended September 30, 2025, the net loss totaled $5,823 million, slightly improved from $6,485 million in the same period of 2024, showing a 10.2% reduction[21] - The company reported a comprehensive loss of $6,681 million for the nine months ended September 30, 2025, compared to $6,485 million in 2024, indicating a 3% increase[21] Operating Expenses - Total operating expenses for the nine months ended September 30, 2025, were $10.595 million, a decrease from $18.932 million in the same period of 2024, reflecting a reduction of about 43.7%[18] - Research and development expenses for the nine months ended September 30, 2025, were $3.819 million, a significant increase compared to $1.196 million in the same period of 2024[18] Cash and Assets - Cash and cash equivalents as of September 30, 2025, were reported at $0, while total current assets decreased to $7.918 million from $13.609 million as of December 31, 2024[16] - The balance of common stock as of June 30, 2025, was $831,424 thousand, an increase from $829,026 thousand as of September 30, 2024[21] - Cash, cash equivalents, and restricted cash at the end of the period were $840,000, up from $722,000 at the end of the previous year[29] Liabilities - Total liabilities as of September 30, 2025, were $83.976 million, a decrease from $90.264 million as of December 31, 2024, showing a reduction of approximately 6.5%[16] - The company has identified material weaknesses in internal controls and is working on remediation efforts[9] - As of September 30, 2025, the Company reported a working capital deficit of $70.3 million and an accumulated deficit of $900.2 million[41] Regulatory and Market Presence - The company anticipates potential changes in regulatory mandates that could impact the coverage of FDA-approved contraceptive products[14] - The company is focused on expanding its market presence and improving its sales and marketing capabilities, particularly after product rebranding efforts[9] Financing and Debt - Interest pertaining to the Baker Notes for the three months ended September 30, 2025, was approximately $2.9 million, and for the nine months ended September 30, 2025, it was approximately $8.5 million[85] - The Baker Notes have a principal amount of up to $25.0 million, with an interest rate of 10.0% per annum[84] - The Company intends to contest the claims of default made by the Designated Agent and Purchasers under the Baker Bros. SPA[110] Inventory and Cost of Goods Sold - The Company expects to significantly reduce its cost of goods sold (COGS) once PHEXX is manufactured under the Windtree License and Supply Agreement[175] - The Company recorded a total of $1.684 million in inventories as of September 30, 2025, compared to $1.577 million as of December 31, 2024[146] Stock and Equity - The Company issued 5,300,000 shares of common stock upon noncash exercise of purchase rights during the reporting period[21] - The Series E-1 Convertible Preferred Stock was authorized to increase from 2,300 to 10,000 shares to facilitate dividend payments in kind, with a conversion price of $0.40 per share[204] - The Series F-1 Shares rank higher than all Common Stock regarding preferences for dividends and distributions upon liquidation[206] Future Outlook - The Company anticipates continuing to incur net losses for the foreseeable future, raising substantial doubt about its ability to continue as a going concern[47] - The Company plans to generate recurring product revenue from PHEXX and SOLOSEC, restructure payables, and seek additional funding through various financing options[45]

Core Points - Evofem Biosciences' shareholders did not approve the merger with Aditxt, leading to the termination of the merger agreement [1] - The company is now focusing on regaining a national stock listing and securing growth capital to achieve sustainable positive EBITDA by 2027 [2] - Evofem has two FDA-approved products: PHEXXI, a hormone-free contraceptive gel, and SOLOSEC, an oral antibiotic for bacterial vaginosis and trichomoniasis [3][5] Company Strategy - The company aims to deliver value for investors and healthcare providers by executing its long-term growth strategy [2] - Collaboration with Aditxt is expected to enhance the commercialization of Mitomic diagnostic tests for women's health conditions [2] Financial Performance - Evofem has experienced four consecutive years of net sales growth as of 2024 [3]

Core Viewpoint - Evofem Biosciences, Inc. has announced that its licensee Pharma 1 has filed for regulatory approval in the UAE to commercialize SOLOSEC, an FDA-approved treatment for bacterial vaginosis and trichomoniasis, targeting a launch in the first half of 2026 [1][2]. Company Overview - Evofem Biosciences focuses on innovative products for women's sexual and reproductive health, generating revenue from two FDA-approved products, SOLOSEC and PHEXXI [9][10]. - Pharma 1, an Emirati healthcare company, holds exclusive commercialization rights for SOLOSEC and PHEXXI in the MENA region, including the UAE, Kuwait, Saudi Arabia, and Qatar [2][13]. Product Details - SOLOSEC is a single-dose oral treatment for bacterial vaginosis and trichomoniasis, providing a complete course of therapy in just one dose [4][11]. - The prevalence of bacterial vaginosis in the MENA region ranges from 25% to 41%, with an estimated 1.0 million to 1.7 million women affected in the UAE alone [4][5]. Market Opportunity - The Gulf Cooperation Council (GCC) region has millions affected by bacterial vaginosis and trichomoniasis, indicating a significant market opportunity for SOLOSEC [2][6]. - The WHO estimated 156.3 million new cases of trichomoniasis globally in 2020, highlighting the ongoing need for effective treatments [5][8]. Strategic Goals - Pharma 1 aims to develop a commercial strategy for SOLOSEC and expects strong reception in the medical community and among patients seeking convenient treatment options [2][3]. - Evofem views this filing as a critical step towards expanding its revenue streams beyond the U.S. market [2][3].